Compare HRL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | VTRS |
|---|---|---|
| Founded | 1891 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 14.2B |
| IPO Year | N/A | N/A |
| Metric | HRL | VTRS |
|---|---|---|
| Price | $23.09 | $12.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $28.00 | $11.50 |
| AVG Volume (30 Days) | 4.6M | ★ 8.6M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.12% | 3.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | $12,106,160,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $2.24 | $1.18 |
| P/E Ratio | $26.31 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $21.03 | $6.85 |
| 52 Week High | $32.07 | $12.73 |
| Indicator | HRL | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 77.18 |
| Support Level | $22.24 | $12.19 |
| Resistance Level | $23.22 | $12.68 |
| Average True Range (ATR) | 0.42 | 0.25 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 39.10 | 95.10 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.